SCA
NKTR icon

SAC Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

SAC Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,915
Closed -$666K – 1902
2013
Q4 		$666K Buy
+3,915
New +$631K ﹤0.01% 1054
2013
Q3 		– Sell
-53,972
Closed -$9.35M – 1887
2013
Q2 		$9.35M Buy
+53,972
New +$8.28M 0.05% 382

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's NKTR Position: Q1 2014 in Review

SAC Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2014, closing a stake of 3,915 shares — an estimated $666K sold.

SAC Capital Advisors first reported a position in NKTR in Q2 2013 and held it in 2 quarters. The position peaked at $9.35M in Q2 2013. 138 funds tracked by Wall St. Rank hold NKTR as of Q1 2014.

  • SAC Capital Advisors reported no remaining Nektar Therapeutics position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 3,915 Nektar Therapeutics shares in Q1 2014, an estimated $666K.
  • SAC Capital Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Nektar Therapeutics position peaked at $9.35M in Q2 2013.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.